Dyadic Applied BioSolutions has entered into a commercial agreement with Opes Diagnostics (Opes) to support the commercial launch of Dyadic’s recombinant human transferrin, bovine transferrin, human FGF and bovine FGF products for use in serum-free cell culture media applications in the life science, food and nutrition markets. 

Under the agreement, Opes will leverage its existing commercial relationships and market experience to identify and engage potential customers primarily in Europe, Israel and Asia to accelerate market entry for Dyadic’s recombinant protein portfolio in cell culture media and related applications, while Dyadic retains the ability to sell directly and to work with additional partners globally.

The collaboration is intended to accelerate the penetration of Dyadic’s recombinant protein products produced using its microbial expression platforms in industries including research, diagnostics, cultured meat and life sciences biomanufacturing that require reliable, scalable and cost-effective sources of growth factors and functional proteins.  Opes has already sampled multiple customers utilising serum free cell culture media in life sciences, food and nutrition applications.

“This collaboration supports our commercial objectives by extending our recombinant protein portfolio in target markets with a partner that has strong, existing sector relationships within the sectors we serve. Opes’ market presence and customer network are expected to help drive adoption of Dyadic’s cell culture media products into expanding markets and to further our shift from primarily development activities to broader commercial engagement,” said Joe Hazelton, President and COO, Dyadic Applied BioSolutions.